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Background: Cytoreductive surgery for metastatic prostate cancer is an emerging area of interest with a
potential upside that includes local control, delayed initiation of hormone therapy, and possibly
improved cancer speciﬁc survival. In order for radical prostatectomy to be an effective treatment option
for men in this group, the beneﬁts must outweigh the surgical morbidity. The aim of this study was to
present a case series and assess the literature feasibility of cytoreductive surgery for men with metastatic
prostate cancer.
Methods: A retrospective review of clinical notes was performed to identify men with metastatic
prostate cancer who underwent cytoreductive surgery between 2012 and 2014 for a group of urologists
at a single institution in Melbourne. Each patient was evaluated with regard to preoperative prostate-
speciﬁc antigen, grade, stage, adjuvant therapy, and surgical outcomes.
Results: Six cases were identiﬁed. This included 1 pelvic exenteration and 5 robot-assisted radical
prostatectomies. The men who underwent RARP had uncomplicated recoveries, regained continence
within 3 months and remained pad-free at follow up. All patients proceeded to additional treatment of
sites of metastatic disease with a variable PSA response, however, 3 of 6 men required recommencement
of ADT for biochemical progression at follow up.
Conclusions: This data supports recent ﬁndings demonstrating that radical prostatectomy for metastatic
prostate cancer is feasible. Further studies are needed to explore the role of cytoreductive surgery with
regards to the potential oncological beneﬁt.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Aggressive cytoreductive surgery for men with metastatic
prostate cancer (PC) is not yet a part of mainstream urology and is
considered by some to be experimental [1], however, there is
growing evidence to support radical prostatectomy (RP) for
selected men with oligometastatic disease. The potential beneﬁts
include prevention of local complications and improved cancer
speciﬁc survival [2,3]. A combined treatment approach incorpo-
rating RP and stereotactic radiation can delay the initiation of
hormone therapy or possibly avoid it altogether. This treatmente, Department of Surgery,
ralia.
Lawrentschuk).
ciﬁc Prostate Society, Published bapproach is still in the exploratory phase and there is a need for
further data from ongoing studies to assess the outcomes for men
undergoing radical surgery in the presence of oligometastatic
prostate cancer.
2. Materials and methods
A retrospective review of clinical notes was performed to
identify men with metastatic prostate cancer who underwent
radical surgery between 2012 and 2014 for a group of urologists at a
single institution in Melbourne. Men included in the data set had
metastatic PC and were offered cytoreductive surgery after careful
discussion with the treating urologist. Outcome was measured by
surgical complications and post-operative continence recovery. Six
cases were identiﬁed e ﬁve men who underwent robot assisted
radical prostatectomy (RARP) and one pelvic exenteration fory Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Summary of Patientsepresenting Features.
Patient Age
(y)
Initial PSA
(ng/mL)
Gleason
score
Clinical stage Sites of metastasis Time from
diagnosis
to surgery
Pre-operative ADT Local symptoms Cytoreductive
surgery
1 77 7.8 4þ5 T2b 7th rib 4 wk e e RARP
2 65 30.0 4þ5 T2b Right inferior pubic ramus 11 mo LHRH agonist Obstructive voiding
symptoms
RARP
3 69 27.0 5þ4 T3b L3 vertebra 4 wk e e RARP
4 49 62.0 4þ4 T2b T11 vertebra 5 y LHRH agonist e RARP
5 68 81.0 4þ3 T4 4th rib, T7 vertebral body 9 y LHRH agonist þ bicalutamide Haematuria, bladder
outlet & ureteric
obstruction
Pelvic
exenteration
6 55 45.0 4þ4 Not known Symphysis pubis, right inferior
pubic ramus, & left internal
iliac node
5 mo LHRH agonist e RARP
ADT, androgen-deprivation therapy; LHRH, luteinizing hormone-releasing hormone; PSA, prostate-speciﬁc antigen; RARP, robot-assisted radical prostatectomy.
Prostate Int 4 (2016) 103e106104metastatic PC with symptoms of locally advanced disease. Their
presenting features are outlined in Table 1. The surgical and onco-
logical outcomes are summarised in Table 2. Each patient was
evaluated with regard to preoperative prostate-speciﬁc antigen,
grade, stage, adjuvant therapy, and surgical outcomes.3. Results
Patients 1e3 presented with solitary bony metastases and
Gleason 9 malignancy on biopsy. Patient 6 presented with two sites
of osseousmetastases in addition to a single lymph nodemetastasis
and Gleason 8 disease on biopsy. These patients were otherwise ﬁt
and well and expressed a strong preference for local treatment,
accepting that: this was not mainstream management; oncologicTable 2
Surgical and Oncologic Outcomes.
Patient Cytoreductive
surgery
Surgical
complications
Final
Gleason
score
Pathological
stage
Surgical
margin
status
Po
PS
1 RARP þ pelvic
lymphadenectomy
e 4þ5 pT3bN1 Negative
2 RARP e 4þ5 pT3bNx Negative
3 RARPþ pelvic
lymphadenectomy
e 5þ4 pT3bN0 Focal positive
margins at
base, apex
4 RARP þ pelvic
lymphadenectomy
e 4þ5 pT3bN0 Positive
5 Pelvic exenteration Colorectal
anastomotic
leak managed
with
defunctioning
stoma
4þ3 pT4N0 N/A
6 RARP Nil 4þ4 pT2c Negative
ADT, androgen-deprivation therapy; LHRH, luteinizing hormone-releasing hormone;
prostatectomy.outcomes could not be easily predicted; and that they could sub-
sequently receive stereotactic radiation to the bony lesions e pa-
tients 2 and 4 proceeding under the auspice of a clinical trial
involving the treatment of men with oligometastatic disease.
Patients 4 and 5 had been diagnosed years earlier and denied
local treatment due to the presence of metastatic disease at pre-
sentation. Patient 4 underwent RARP after his PSA had remained
stable for 5 years on androgen deprivation therapy (ADT). Patient 5
had undergone radiation to a solitary rib metastasis at presentation
9 years earlier following which ADT was commenced. He was
referred with castrate resistant disease and signiﬁcant local pro-
gression causing recurrent urosepsis, haematuria, ureteric
obstruction and obstructive voiding, but no sign of metastatic
progression on restaging. Given the profound symptomatologystoperative
A (ng/mL)
Postoperative
ADT
Postoperative
radiation
Follow-up
(mo)
Follow-up
continence
Follow-up
PSA
(ng/mL)
1.23 e Stereotactic
radiation to
7th rib
8 Pad-free 0.36
0.77 LHRH
agonist þ
bicalutamide
Stereotactic
radiation to
pubic ramus
(POPSTAR
trial)
21 Pad-free 0.44
19.9 LHRH
agonist þ
bicalutamide
Stereotactic
radiation to
L3 vertebra
21 Pad-free 4.7
< 0.1 LHRH agonist Adjuvant
radiotherapy,
subsequent
stereotactic
radiation to
right iliac
lesion
(POPSTAR
trial)
36 Pad-free 0.1
0.3 Nil Stereotactic
radiation to
newmetastatic
lesions 7 mo.
Post-op
(pelvic lymph
node, ilium, rib)
10 Ileal conduit 5.1
< 0.01 LHRH agonist
(ceased 2 mo.
post- RARP)
Stereotactic
radiation to
three
metastatic sites
17 Pad-free 0.07
N/A, not applicable; PSA, prostate-speciﬁc antigen; RARP, robot-assisted radical
Katelaris et al / Cytoreductive surgery for men 105related to the locally invasive pelvic malignancy he elected for
cystoprostatectomy/anterior resection.
Patients 1e4 and 6 had an uncomplicated recovery from RARP
with amedian hospital stay of 2 days (1e3). All regained continence
within 3 months and remain pad free at follow-up. Patient 5
required temporary colonic diversion for a rectal anastomotic leak
and subsequently recovered well. All patients proceeded to addi-
tional treatment to sites of metastatic disease with a variable PSA
response, however at follow-up, three of the six men have required
recommencement of ADT for biochemical progression. Notably, in
the three men on ADT pre-operatively the PSA remains lower after
aggressive treatment of local and metastatic disease, and at follow-
up none of the men have local symptoms from malignancy or the
surgery. A surgical approach has demonstrated beneﬁt without
deleterious effect in these cases.
4. Discussion
Locally advanced PC is a highly morbid condition. The compli-
cations of uncontrolled pelvic malignancy include recurrent
bladder neck obstruction requiring transurethral resection of the
prostate, gross haematuria that can be difﬁcult to control, rectal
compression requiring stoma, ureteric obstruction, and pelvic
nerve inﬁltration causing intractable pain. Therefore, palliative
surgery should be considered even if a cure is not achievable due to
the presence of metastatic disease.4 RP in the presence of oligo-
metastatic disease should be considered in the context of deﬁnitive
palliation, and also for its potential to improve cancer-speciﬁc
survival.5 The presented data is retrospective, small and uncon-
trolled, it demonstrates that surgery can be safely performed in this
patient group with minimal morbidity. Ideally, a randomized study
should be performed comparing surgery þ ADT to ADT alone;
however, this type of study design presents several challenges,
including difﬁculty in obtaining consent for randomization due to a
desire to be in the surgery group.
Aggressive local control with RP is only justiﬁed if the surgical
morbidity is very low. Our experience with RARP for selected men
with metastatic PC is that of a low morbidity procedure (see
Table 1), despite the high-risk patient group. This supports the
ﬁndings presented by Heidenreich et al,2 particularly with regard to
the excellent postoperative continence. The minor postoperative
morbidity was similar to that of RP for men with localized disease.
All cases presented were performed at high volume units with
experienced operators. In these circumstances, we believe the risk-
beneﬁt analysis is in favor of RP rather than ADT alone. The proven
palliative beneﬁt of RP for selected men with metastatic PC2,6 was
also demonstrated in that no palliative procedures were required
following deﬁnitive local treatment. There was no mortality for the
ﬁve patients presented, notwithstanding a short follow-up period.
A survival beneﬁt for men undergoing RP for metastatic disease
has yet to be proven, despite the increasing body of evidence that
supports it.2,7e9 It seems reasonable to offer RP to selected, well-
informed men with metastatic PC. The use of stereotactic radia-
tion for the treatment of oligometastatic disease means that men in
this group may have the chance to be cured. The use of Cyberknife
stereotactic radiosurgery has been demonstrated to be useful in
men with low-volume bony metastases,10 and the use of stereo-
tactic radiation for oligometastatic disease following primary sur-
gical treatment of PC is currently under investigation (POPSTAR
trial) in Melbourne. A multimodal approach, including primary
surgery, radiation, and ADT, seems to provide the most compre-
hensive treatment strategy.
To deﬁnitively treat PC with oligometastatic disease, it is
necessary to control the primary with RP and the oligometastatic
disease with stereotactic radiation therapy. The advent of theprostate-speciﬁc membrane antigen (PSMA) positron emission to-
mography (PET) scan may have an important role in the manage-
ment of men with oligometastatic disease. Currently, PSMA PET
scanning is primarily being used to detect PC recurrence in the
context of a rising PSA.11,12 However, its ability to identify lymph
node and osseous metastases means that it has the potential to
facilitate treatment of metastases with stereotactic radiosurgery,
which, in turn, may improve cancer-speciﬁc survival in men with
metastatic PC. Men with oligometastatic disease in whom the pri-
mary tumor is effectively treated may die from their distant dis-
ease. By identifying the site of distant disease, PSMA PET scanning
may enable treatment of the distant disease with stereotactic ra-
diation, possibly improving survival rates.
Although PSMA PET scanning still needs to be validated
through rigorous trials, it may well be used as a primary pre-
operative staging modality13,14 superseding CT and nuclear-
medicine bone scans. The rapid introduction of PSMA PET scan-
ning into clinical practice means there are a growing number of
men who are being classiﬁed as having M1 disease, because it is
more sensitive than traditional imaging techniques. It is, therefore,
particularly important in the PSMA era for further studies inves-
tigating the role of aggressive local treatment in men with oligo-
metastatic PC. Indeed, it may prove deleterious to deny men with
M1 disease aggressive local treatment based on ultra-sensitive
PSMA ﬁndings.
Aggressive treatment of men with oligometastatic disease in-
cludes deﬁnitive treatment of the primary. The options for this
include radical surgery or radical radiation therapy. Surgery has
several advantages over radiation therapy for men with metastatic
PC. The advantages include arguably better local control, particu-
larly for high-grade disease, and the option of salvage radiation for
multimodal local therapy with options available for treatment of
permanent side effects, such as urinary incontinence, should they
occur. With effective treatment of the primary cancer and the oli-
gometastatic disease with stereotactic radiation, it may be that ADT
can be avoided, or at least signiﬁcantly delayed, thereby reducing
the associated morbidity.
5. Conclusions
Minimally invasive RARP combined with the increasing sophisti-
cation of imaging (PSMA PET scanning) and radiation therapy pro-
vides a safe, feasible means of treating carefully selected men with
metastatic PC, with the potential for cure or improved cancer-speciﬁc
survival, in addition to preventing local complications. This data
supported previous ﬁndings that RP in the setting of low-volume
metastatic PC is a feasible procedure without increase in morbidity.
Further data is needed in order to substantiate these ﬁndings.
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